Alzheimer disease (AD) is a complex neurodegenerative disorder, whose prevalence will dramatically rise by 2050. Despite numerous clinical trials investigating this disease, there is still no effective treatment. Many trials showed negative or inconclusive results, possibly because they recruited only patients with severe disease, who had not undergone disease-modifying therapies in preclinical stages of AD before severe degeneration occurred. Detection of AD in asymptomatic at risk individuals (and a few presymptomatic individuals who carry an autosomal dominant monogenic AD mutation) remains impractical in many of clinical situations and is possible only with reliable biomarkers. In addition to early diagnosis of AD, biomarkers should ser...
The diagnostic guidelines of Alzheimer's disease (AD) have recently been updated to include brain im...
The past five years have seen an enormous development in the field of fluid biomarkers for Alzheimer...
Recent advances in biomarker studies on dementia are summarized here. CSF Aβ40, Aβ42, total tau, an...
Alzheimer disease (AD) is a complex neurodegenerative disorder, whose prevalence will dramatically r...
BACKGROUND: Current research criteria for Alzheimer's disease (AD) include cerebrospinal fluid (CSF)...
Accumulating data from the clinical research support that the core Alzheimer's disease (AD) cerebros...
Background and Objectives: The search for accurate biomarkers in Alzheimer Disease (AD), on of the m...
Introduction: Alzheimer’s disease (AD) is a neurodegenerative disease affecting the brain. Today the...
Alzheimer disease (AD) is a neurodegenerative disorder characterized by significant cognitive defici...
Alzheimer's disease (AD) is a progressive neurodegenerative disease and the single commonest cause o...
Biomarkers in Alzheimer's disease (AD) have the potential to allow early and more accurate diagnosis...
Background: Current research criteria for Alzheimer’s disease (AD) include Cerebrospinal Fluid (CSF)...
A major barrier to the effective conduct of clinical trials of new drug candidates against Alzheimer...
Alzheimer’s disease (AD) is a slow and progressive neurodegenerative disorder.With new treatment str...
Research progress has provided detailed understanding of the molecular pathogenesis of Alzheimer dis...
The diagnostic guidelines of Alzheimer's disease (AD) have recently been updated to include brain im...
The past five years have seen an enormous development in the field of fluid biomarkers for Alzheimer...
Recent advances in biomarker studies on dementia are summarized here. CSF Aβ40, Aβ42, total tau, an...
Alzheimer disease (AD) is a complex neurodegenerative disorder, whose prevalence will dramatically r...
BACKGROUND: Current research criteria for Alzheimer's disease (AD) include cerebrospinal fluid (CSF)...
Accumulating data from the clinical research support that the core Alzheimer's disease (AD) cerebros...
Background and Objectives: The search for accurate biomarkers in Alzheimer Disease (AD), on of the m...
Introduction: Alzheimer’s disease (AD) is a neurodegenerative disease affecting the brain. Today the...
Alzheimer disease (AD) is a neurodegenerative disorder characterized by significant cognitive defici...
Alzheimer's disease (AD) is a progressive neurodegenerative disease and the single commonest cause o...
Biomarkers in Alzheimer's disease (AD) have the potential to allow early and more accurate diagnosis...
Background: Current research criteria for Alzheimer’s disease (AD) include Cerebrospinal Fluid (CSF)...
A major barrier to the effective conduct of clinical trials of new drug candidates against Alzheimer...
Alzheimer’s disease (AD) is a slow and progressive neurodegenerative disorder.With new treatment str...
Research progress has provided detailed understanding of the molecular pathogenesis of Alzheimer dis...
The diagnostic guidelines of Alzheimer's disease (AD) have recently been updated to include brain im...
The past five years have seen an enormous development in the field of fluid biomarkers for Alzheimer...
Recent advances in biomarker studies on dementia are summarized here. CSF Aβ40, Aβ42, total tau, an...